고관절 연속식 수동 운동장치 시장 : 조작 모드, 장비 유형, 최종사용자, 유통 채널, 용도별 - 예측(2026-2032년)

The Hip Continuous Passive Motion Device Market was valued at USD 384.87 million in 2025 and is projected to grow to USD 409.03 million in 2026, with a CAGR of 5.69%, reaching USD 567.27 million by 2032.

Positioning hip continuous passive motion devices within modern care pathways to address clinical needs, operational efficiency, and evolving patient expectations

The introduction frames the contemporary relevance of hip continuous passive motion devices within a healthcare environment that prizes accelerated recovery, reduced complication rates, and enhanced patient autonomy. Clinicians and care managers increasingly seek interventions that improve postoperative mobility while minimizing resource burden, and devices that deliver controlled joint movement are central to these objectives. Consequently, stakeholders from device innovators to care delivery organizations are recalibrating protocols, procurement criteria, and patient education to incorporate motion therapy as a core component of perioperative and rehabilitative pathways.

Against this backdrop, the device landscape is evolving along multiple dimensions: technological refinement of control interfaces, diversification of power sources to enable true home use, and reorientation of distribution channels to meet the expectations of digitally enabled patients. Transitioning clinical practice patterns and payer scrutiny are raising the bar for evidence generation, usability, and cost-effectiveness. Therefore, this introduction establishes the device category as an intersection of clinical utility, engineering design, and commercial strategy, and sets the stage for a deeper examination of market forces, regulatory influences, and segmentation-driven opportunities that follow.

How clinical priorities, digital enablement, and evidence-driven procurement are redefining adoption and innovation in hip continuous passive motion devices

Transformative shifts in the landscape are driven by converging pressures from clinical practice, technology maturation, and patient-centric care models. Enhanced perioperative protocols emphasize early mobilization to reduce length of stay and lower complication risks, which elevates the role of motion devices as facilitators of standardized rehabilitation. Concurrently, advances in programmable control systems and user interfaces are enabling more precise therapy regimens, while lower-power electronics and modular designs broaden the feasibility of outpatient and home-based applications.

Moreover, reimbursement frameworks and hospital procurement are increasingly tied to demonstrable outcomes, compelling manufacturers to invest in clinical studies and integrate data capture capabilities into their devices. This shift encourages partnerships between clinical stakeholders and device developers to validate efficacy and track long-term functional outcomes. Digital enablement and remote monitoring are also redefining clinician oversight of at-home therapy, enabling adaptive protocols that respond to patient progress. Taken together, these shifts are reshaping adoption drivers, influencing product roadmaps, and creating new vectors for differentiation across design, service, and evidence generation.

Assessing how 2025 tariff adjustments altered sourcing, pricing, and supply chain resilience for hip continuous passive motion devices in the United States

The cumulative impact of tariff changes in the United States during 2025 introduced a layer of complexity to device sourcing, cost structures, and strategic supply chain planning. For manufacturers and distributors that rely on cross-border component procurement or finished goods importation, altered tariff regimes necessitated reassessments of supplier contracts, landed cost calculations, and pricing strategies to preserve margin and maintain competitive parity. These developments prompted near-term inventory adjustments and longer-term supplier diversification initiatives.

In response, manufacturers accelerated evaluation of domestic assembly options and regional manufacturing partnerships to mitigate exposure and reduce logistics lead times, while channel partners adjusted contract terms to absorb or pass through incremental costs depending on competitive positioning. At the same time, clinical purchasers and hospital supply chain teams heightened scrutiny on total cost of ownership and sought bundled service agreements that offset potential price increases. The tariff landscape therefore acted as a catalyst for more resilient sourcing strategies, reinforced the strategic importance of value-based contracting, and encouraged stakeholders to consider localization and vertical integration where feasible to protect continuity of supply and price stability.

Segment-driven strategies that align operation modes, end-user needs, distribution pathways, device architectures, and clinical applications to accelerate adoption

Key segmentation insights reveal how distinct product, channel, and clinical dimensions shape competitive dynamics and buyer requirements. When analyzing devices by operation mode, distinctions between non-programmable devices and programmable devices are instructive: non-programmable variants typically prioritize simplicity and lower cost and are available as AC-powered units and battery-operated units that support portability, while programmable devices emphasize tailored regimens and sophisticated control through digital interfaces or mechanical interfaces, influencing clinician preference and reimbursement pathways.

End-user segmentation further differentiates requirements across ambulatory surgical centers, home healthcare, and hospitals. Ambulatory surgical centers encompass both hospital-owned centers and independent centers with divergent procurement cycles and capital constraints. Home healthcare settings include direct-to-consumer rental models and professional home healthcare providers that demand robust patient support and remote monitoring. Hospitals split into general hospitals and orthopedic specialty hospitals, each imposing unique clinical workflows, volume expectations, and evidence thresholds.

Distribution channel dynamics are equally consequential, spanning direct sales, e-commerce platforms, and third-party distributors. Direct sales often route through group purchasing organization arrangements and original equipment manufacturer sales teams; e-commerce includes manufacturer online stores alongside third-party online platforms; third-party distributors range from full-line distributors to those specialized in devices. Device type delineations between home-based devices and hospital-based devices inform design trade-offs where home-based options can be owned or rental models, and hospital-based formats vary between free-standing and table-top mounted units. Finally, application segmentation across chronic management, injury rehabilitation, and postoperative rehabilitation frames clinical value propositions: chronic management addresses degenerative joint disease and osteoarthritis, injury rehabilitation covers sports and traumatic injuries, and postoperative rehabilitation encompasses hip resurfacing and total hip replacement pathways. Collectively, these segmentation lenses illuminate targeted product development, tailored go-to-market approaches, and differentiated service models that resonate with specific buyer cohorts.

Regional pathways and commercialization levers that tailor product, evidence, and channel strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional insights underscore differentiated demand drivers, regulatory environments, and commercialization pathways across major global markets. In the Americas, healthcare delivery emphasizes integrated hospital systems, outpatient surgical growth, and an increasingly active homecare market where reimbursement and purchaser consolidation influence procurement strategies. This region tends to favor devices that demonstrate operational efficiency and clear postoperative outcome benefits, and strategic partnerships with large health systems can materially accelerate adoption.

In Europe, Middle East & Africa, fragmented reimbursement systems and diverse regulatory requirements create both challenges and opportunities; national-level health technology assessments and device registration processes influence launch sequencing, while private-sector growth in certain urban markets supports earlier uptake of innovative programmable devices. Stakeholders in this geography often prioritize robust clinical evidence and localized support infrastructure to ensure clinician confidence and patient adherence.

Asia-Pacific presents a dynamic mix of high-volume public hospital systems, expanding private care, and growing consumer demand for at-home solutions. Rapid urbanization and investments in outpatient services are enabling new distribution models, while local manufacturing and regulatory acceleration in several markets can shorten commercialization timelines. Each region therefore requires calibrated market-entry tactics, evidence generation strategies, and channel partnerships that reflect local reimbursement, clinical practice, and patient behavior patterns.

Competitive differentiation through evidence-enabled devices, adaptive distribution strategies, and manufacturing agility to strengthen market positioning

Insights on leading companies highlight how strategic choices in product design, clinical evidence, channel orchestration, and service delivery determine market positioning. Industry leaders are differentiating by integrating data capture and remote monitoring capabilities into devices to support outcome measurement and to create recurring revenue models through service contracts. Others concentrate on modular, low-cost platform designs that facilitate scale across rental and owned models, enabling penetration of value-conscious channels such as independent ambulatory centers and direct-to-consumer homecare.

Competitive advantage also emerges from distribution sophistication: some firms emphasize direct relationships with health systems and group purchasing organizations to secure preferred-supplier status, while others expand e-commerce capabilities and partnerships with specialized distributors to reach homecare and smaller hospital segments. Strategic collaborations with rehabilitation providers and payers are being used to generate real-world evidence and to support reimbursement narratives. Finally, investments in manufacturing flexibility and regional partnerships are enabling faster response to tariff dynamics and shifting demand, reinforcing supply continuity and supporting localized go-to-market strategies.

Practical strategic moves to boost adoption, secure reimbursement, and build resilient supply and distribution models for continuous motion hip devices

Actionable recommendations for industry leaders focus on aligning product roadmaps with payer expectations, clinical workflows, and patient experience imperatives. First, prioritize integration of evidence generation into product development by designing prospective clinical programs and pragmatic studies that demonstrate functional outcomes and cost-effectiveness, thereby supporting procurement and reimbursement discussions. Second, enhance device usability through intuitive interfaces and reliable power options to broaden suitability for home-based therapy and reduce the burden on clinical staff.

Third, diversify distribution by balancing direct health system engagement with scalable e-commerce models and selective third-party distributor relationships to optimize reach across hospitals, ambulatory centers, and homecare. Fourth, fortify supply chains through regional manufacturing partnerships or flexible contract manufacturing to mitigate tariff exposure and logistics disruption. Finally, develop service-led revenue streams that include rentals, remote monitoring, and support packages to create predictable lifetime value and to differentiate offerings on post-sale performance and adherence support. Executing these recommendations will accelerate adoption, strengthen commercial resilience, and improve patient outcomes.

Rigorous mixed-methods research combining stakeholder interviews, clinical literature review, regulatory analysis, and cross-sectional segmentation to underpin strategic findings

The research methodology combines a multi-source evidence base, stakeholder interviews, and qualitative analysis to ensure robust and actionable conclusions. Primary research included structured interviews with clinicians, rehabilitation specialists, hospital procurement leaders, device manufacturers, and distribution partners to capture firsthand perspectives on clinical utility, purchasing drivers, and operational constraints. These conversations informed the identification of key themes in product design, channel dynamics, and evidence needs.

Secondary analysis synthesized regulatory guidance, clinical literature, and publicly available policy documentation to contextualize clinical adoption barriers and reimbursement considerations. Comparative analysis across operation modes, end-user segments, distribution channels, device types, and applications enabled consistent mapping of needs to product and go-to-market solutions. Cross-validation with supply chain and manufacturing data provided additional rigor on sourcing and tariff-related implications. Throughout, the approach emphasized triangulation of insights to reduce bias and to highlight implications that are directly relevant to decision-makers seeking to prioritize investments and actions.

Synthesis of strategic imperatives showing how evidence, design, and commercial agility will determine long-term success in the hip continuous passive motion device category

The conclusion synthesizes the central narrative: hip continuous passive motion devices are transitioning from niche postoperative adjuncts to integral components of modern rehabilitation strategies through technological refinement, evidence-based validation, and distribution innovation. Stakeholders that align product design with clinician workflow, demonstrate measurable outcomes, and create flexible commercial models will capture the most compelling opportunities. The interplay of tariff dynamics, regional regulatory variation, and evolving payer expectations underscores the need for adaptable supply chains and localized commercialization plans.

Looking ahead, the category's future momentum will hinge on its ability to deliver both clinical benefits and operational value, to scale service-led models that enhance adherence, and to partner effectively with care providers and payers to embed devices within standardized care pathways. Firms that combine compelling clinical evidence, user-centric design, and multi-channel distribution will be best positioned to translate innovation into sustained clinical impact and commercial success.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hip Continuous Passive Motion Device Market, by Operation Mode

• 8.1. Non-Programmable Devices
  • 8.1.1. AC-Powered
  • 8.1.2. Battery-Operated
• 8.2. Programmable Devices
  • 8.2.1. Digital Interface
  • 8.2.2. Mechanical Interface

9. Hip Continuous Passive Motion Device Market, by Device Type

• 9.1. Home-Based Devices
• 9.2. Hospital-Based Devices

10. Hip Continuous Passive Motion Device Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Home Healthcare
• 10.3. Hospitals

11. Hip Continuous Passive Motion Device Market, by Distribution Channel

• 11.1. Offline
• 11.2. Online

12. Hip Continuous Passive Motion Device Market, by Application

• 12.1. Chronic Management
  • 12.1.1. Degenerative Joint Disease Management
  • 12.1.2. Osteoarthritis Management
• 12.2. Injury Rehabilitation
  • 12.2.1. Sports Injuries
  • 12.2.2. Traumatic Injuries
• 12.3. Postoperative Rehabilitation
  • 12.3.1. Hip Resurfacing
  • 12.3.2. Total Hip Replacement

13. Hip Continuous Passive Motion Device Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Hip Continuous Passive Motion Device Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Hip Continuous Passive Motion Device Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Hip Continuous Passive Motion Device Market

17. China Hip Continuous Passive Motion Device Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. BMS
• 18.6. Breg, Inc.
• 18.7. Chattanooga International
• 18.8. Chirag Electronics Pvt. Ltd.
• 18.9. CONMED Corporation
• 18.10. DePuy Synthes
• 18.11. DJO Global, Inc.
• 18.12. HMS Medical Systems
• 18.13. India Medico Instruments
• 18.14. Kinetec
• 18.15. Medline Industries, LP
• 18.16. NC Medical Systems
• 18.17. OPED
• 18.18. OrthoRehab, Inc.
• 18.19. Physio Care Devices
• 18.20. Prasaditi Medical Equipments
• 18.21. Rimec
• 18.22. Smith & Nephew PLC
• 18.23. Stryker Corporation
• 18.24. Technomed Electronics
• 18.25. Zimmer Biomet Holdings, Inc.
• 18.26. Ossur hf.